Culture solution for cell source for bioartificial liver

A bioartificial and culture medium technology, applied in the field of hepatocyte and hepatocyte-like culture, can solve the problems of hepatocyte apoptosis and inability to resist high bilirubin toxicity, so as to improve curative effect, increase survival rate and survival time, and promote Effects on Hepatocyte Growth

Active Publication Date: 2014-07-30
WUHAN TOGO MEDITECH CO LTD
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The purpose of the present invention is to overcome the defect that the existing hepatocyte culture medium cannot resist high bilirubin toxicity and easily cause apoptosis of hepatoc

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Prepare 1L of cell-derived culture medium 1 for bioartificial liver, the formula is as follows:

[0029] 899mL low-sugar DMEM (L) culture medium

[0030] 111mL fetal bovine serum (Hyclone company)

[0031] 60U insulin

[0032] 9 μg hepatocyte growth factor

[0033] 0.5g magnesium isoglycyrrhizinate

[0034] 10mg tauroursodeoxycholic acid

[0035] 50000U green chain double antibody (penicillin-streptomycin / Gibco company).

[0036] When preparing, you can add part of the low-sugar DMEM (L) culture solution first, and then add the remaining low-sugar DMEM (L) culture solution to make up to 1L after all other substances are added.

Embodiment 2

[0038] Prepare 1L of cell-derived culture medium 2 for bioartificial liver, the formula is as follows:

[0039] 923mL low-sugar DMEM (A) culture medium

[0040] 77mL fetal bovine serum (Hyclone company)

[0041] 140U insulin

[0042] 3 μg hepatocyte growth factor

[0043] 2g magnesium isoglycyrrhizinate

[0044] 3mg tauroursodeoxycholic acid

[0045] 100000U green chain double antibody (penicillin-streptomycin / Gibco company).

[0046] When preparing, you can add part of the low-sugar DMEM (L) culture solution first, and then add the remaining low-sugar DMEM (L) culture solution to make up to 1L after all other substances are added.

Embodiment 3

[0048] Prepare 1L of cell-derived culture medium 3 for bioartificial liver, the formula is as follows:

[0049] 909mL low-sugar DMEM (L) culture medium

[0050] 91mL fetal bovine serum (Hyclone company)

[0051] 80U insulin

[0052] 6 μg hepatocyte growth factor

[0053] 1.2g magnesium isoglycyrrhizinate

[0054] 5mg tauroursodeoxycholic acid

[0055] 60000U green chain double antibody (penicillin-streptomycin / Gibco company).

[0056] When preparing, you can add part of the low-sugar DMEM (L) culture solution first, and then add the remaining low-sugar DMEM (L) culture solution to make up to 1L after all other substances are added.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a culture solution for a cell source for a bioartificial liver. The culture solution comprises a mixed solution comprising a low-sugar type DMEM culture solution and fetal bovine serum according to the volume ratio of (8-12): 1, wherein the mixed solution further contains 60-140U/L of insulin, 3-9mu g/L of hepatocyte growth factor, 0.5-2g/L of magnesium isoglycyrrhizinate, 3-10mg/L of tauroursodeoxycholic acid and 50-100U/ml of green chain double-antibody. The culture solution for the cell source for the bioartificial liver disclosed by the invention can promote the growth of hepatocytes or hepatocyte-like cells, is conductive to developing the cells to the direction of better realizing liver functions, particularly can effectively improve the survival rate and the survival time of the cells in a hyperbilirubinemia environment and improve the curative effect by improving an existing DMEM culture medium and adding insulin for protecting the hepatocytes, hepatocyte growth factor, magnesium isoglycyrrhizinate and tauroursodeoxycholic acid. The culture solution is suitable for culturing various hepatocytes and hepatocyte-like cells, in particular to L-02 cells.

Description

technical field [0001] The invention relates to the technical field of hepatocyte and hepatocyte-like culture, in particular to a cell-source culture solution for a bioartificial liver. Background technique [0002] my country is the country with the most serious liver disease in the world, with more than 1 million new cases of liver failure each year, and about 500,000 liver failure patients die each year due to lack of effective treatment. There is only one chance of cure, that is, liver transplantation, but due to the difficulty in obtaining livers, the long waiting time, or no chance to get a donor liver at all, most patients have no chance of survival at all. Therefore, an artificial liver system is urgently needed to maintain the patient's life, waiting for the opportunity of liver transplantation, or the opportunity of the patient's own liver recovery. [0003] However, due to the high cost of the traditional artificial liver (that is, the physical artificial liver),...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N5/071
Inventor 周平刘路
Owner WUHAN TOGO MEDITECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap